Furthermore, our recent work employing single cell (sc) RNA-seq analysis of the TME of murine breast cancer treated with effective multimodal intralesional therapy revealed that Slamf6 was not expressed on naive or terminally-exhausted T cells16, suggesting that Slamf6 might be a valuable marker to predict response to immunotherapy. This evidence concerns the gene SLAMF6 and breast carcinoma.